Abstract:Acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure characterized by hypoxemia, pulmonary edema not explained by cardiac failure or fluid overload, and diffuse bilateral radiographic opacities occurring in the presence of a predisposing factor.1,2 No approved drug therapy for ARDS exists. Thus, treatment for ARDS is based on management of the underlying disease and supportive care. Despite substantial progress in ventilatory strategies, the hospital mortality rate of ARDS remains approximately 40%.3 The key pathophysiological event underlying ARDS is an uncontrolled inflammatory response resulting in injury to the epithelium and endothelium of the alveolar-capillary barrier with increased pulmonary vascular leakage.1,2
Abstract:An estimated 266 million operations were performed worldwide in 2015.1 One of the risks patients commonly face is intraoperative hypotension. A previous study involving 255 patients reported that 87% experienced 1 or more hypotensive episodes intraoperatively (with hypotension defined as a mean arterial pressure [MAP] <65 mm Hg).2 Reported causes are anesthetic drugs, existing comorbidities, and surgical manipulation.3,4
Abstract:Since December 8, 2019, an epidemic of coronavirus disease 2019 (COVID-19) has spread rapidly.1 As of February 6, 2020, China reported 31 211 confirmed cases of COVID-19 and 637 fatalities.